QTERN

This brand name is authorized in Austria, Australia, Brazil, Estonia, Finland, Ireland, Lithuania, Poland, Romania, Turkey, United Kingdom, United States

Active ingredients

The drug QTERN contains a combination of these active pharmaceutical ingredients (APIs):

1 Saxagliptin UNII Z8J84YIX6L - SAXAGLIPTIN HYDROCHLORIDE

Saxagliptin is a highly potent (Ki: 1.3 nM), selective, reversible, competitive, DPP4 inhibitor. Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes. Read about Saxagliptin

2 Dapagliflozin UNII 887K2391VH - DAPAGLIFLOZIN PROPANEDIOL

Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Dapagliflozin improves both fasting and post-prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary glucose excretion. Read about Dapagliflozin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
QTERN Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BD21	Saxagliptin and dapagliflozin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11286B, 11305B
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502320030033807, 502320030033907
Country: EE	Ravimiamet	Identifier(s): 1725511, 1725522, 1725533, 1725544
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 026471, 504230
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 336824
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1080763, 1080764, 1080765, 1080766
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100375292
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W63069001
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699786092884, 8699786092891
Country: US	FDA, National Drug Code	Identifier(s): 0310-6770, 0310-6780